Yesterday, I interviewed Thomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, about his new book, PharmaPhobia, and his call to action against the "Conflict of Interest Movement," which he claims undermines American medical innovation. Show More Summary
The comments are in! As usual, the pharma industry waited until the last second to submit comments to FDA Docket 2013-N-1430 regarding "Guidance for Industry: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive...Show More Summary
In just a few weeks, I will be announcing the recipient(s) of the 4th Annual Pharmaguy Social Pioneer Award at the Digital Pharma East conference in Philadelphia. s part of the ceremony, I will pass on the famous -- or infamous, depending...Show More Summary
A few months ago, I engaged Peter Houston (@Flipping_Pages) in a discussion about whether or not pharma "should" do Tumblr, a social media site that allows users to post text, photos, quotes, links, music, and videos from browsers, phones, via email or wherever (see "Should Pharma Do Tumblr?"). Show More Summary
Science Weekly Extra: An extended interview with Ben Goldacre on Bad Pharma http://audio.theguardian.tv/audio/kip/science/series/science/1350653685662/7287/gnl.sci.120122.jp.science_weekly_goldacrefull.mp3 In Science Extra this weekShow More Summary
The issue of drug shortages has surfaced periodically in the news and in policy circles for months, prompting both FDA and the Administration to various actions. For some, it may be an abstract notion – the idea that some drugs … Continue reading ?
As if hearing my voice on the page isn't enough, here's a podcast I did last week with Paul Howard of the Manhattan Institute on the FDA's Avastin decision. You might think that they'd be all worked up about this (a la the Wall Street Journal's editorial page), but you might be surprised...
The past two days have been focused on The Physician Payment Sunshine provisions of the Patient Protection Affordable Care Act in the U.S. which will require the reporting of financial relationships between medical product manufacturers and medical providers by 2013. … Continue reading ?
Here's an interview that I did recently with Paul Howard of the Manhattan Institute on the results of that immunotherapy leukemia trial (and on some broader topics around the current state of drug discovery). Anyone who would like to...Show More Summary
It is another one of those questions – how did we get here? For months FDA’s DDMAC did not seem to understand the impact of social media, then asked for help understanding how to regulate it, then failed to produce … Continue readi...
23 May 2011 The need for new ways to define disease listen now | download audio In a series of articles in the British Medical Journal Australian medical journalist Ray Moynihan argues that there are problems in the way diseases are defined. Show More Summary